Verification evidence is still being completed.
PDF / print export
Rokote Laboratories Finland
Kuopio, Finland
- Verified lead
- Erkko Ylosmaki
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Nasal Adenoviral-Vector Vaccines, COVID-19 and Respiratory Programs, and Phase 1 Clinical Operations
- Review cycle
- 24 April 2026
- Full address
- Microkatu 1 L, 70210 Kuopio, Finland (Novapolis)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- University of Eastern Finland announcement of the Rokote Laboratories CEO transition naming Erkko Ylosmaki.
- Editorial note
- Kuopio clinical-stage nasal adenoviral vaccine biotech with named CEO, first-in-human trials at Kuopio University Hospital, and partner GMP supply through KCT.
Nasal Adenoviral-Vector Vaccines, COVID-19 and Respiratory Programs, and Phase 1 Clinical Operations
Public CEO disclosure via UEF, Phase 1 clinical-trial documentation, Partner GMP supply
Kuopio clinical-stage nasal adenoviral vaccine biotech with named CEO, first-in-human trials at Kuopio University Hospital, and partner GMP supply through KCT.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Kuopio, Finland
Rokote Laboratories Finland
Nasal Adenoviral-Vector Vaccines, COVID-19 and Respiratory Programs, and Phase 1 Clinical Operations · Clinical-stage vaccine development
Kuopio clinical-stage nasal adenoviral vaccine biotech with named CEO, first-in-human trials at Kuopio University Hospital, and partner GMP supply through KCT.
- Lead
- Erkko Ylosmaki (verified ↗)
- Address
- Microkatu 1 L, 70210 Kuopio, Finland (Novapolis) (source ↗)
- Compliance
- Partner GMP supply
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage vaccine development
- Capabilities
- Adenoviral-Vector Vaccine Design · Nasal Delivery Formulation · Phase 1 Clinical Operations
- Founded
- 2020
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Erkko Ylosmaki
Chief Executive Officer
Full addressMicrokatu 1 L, 70210 Kuopio, Finland (Novapolis)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Rokote Laboratories contact page listing the Microkatu 1 L Novapolis address.
Open sourceClinical-stage vaccine development
Kuopio, Finland. Nasal Adenoviral-Vector Vaccines, COVID-19 and Respiratory Programs, and Phase 1 Clinical Operations. Review completed on 24 Apr 2026.
Fimea and EMA for clinical oversight
Public CEO disclosure via UEF, Phase 1 clinical-trial documentation, Partner GMP supply
Nasal Adenoviral-Vector Vaccines, COVID-19 and Respiratory Programs, and Phase 1 Clinical Operations
Kuopio clinical-stage nasal adenoviral vaccine biotech with named CEO, first-in-human trials at Kuopio University Hospital, and partner GMP supply through KCT.
Editorial note
Rokote Laboratories Finland is a University of Eastern Finland-linked vaccine biotech with a named CEO since January 2024, a Phase 1 clinical programme for its nasal COVID-19 vaccine, and partner GMP supply through KCT.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Adenoviral-Vector Vaccine Design
Nasal Delivery Formulation
Phase 1 Clinical Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Adenoviral-vector design workflow
Clinical trial operations
University of Eastern Finland collaboration
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Rokote Laboratories Finland located?
- Rokote Laboratories Finland operates from Microkatu 1 L, 70210 Kuopio, Finland (Novapolis), Kuopio, Finland.
- Who runs Rokote Laboratories Finland?
- Rokote Laboratories Finland is led by Erkko Ylosmaki, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does Rokote Laboratories Finland hold?
- Rokote Laboratories Finland is documented under Partner GMP supply.
- What does Rokote Laboratories Finland do?
- Kuopio clinical-stage nasal adenoviral vaccine biotech with named CEO, first-in-human trials at Kuopio University Hospital, and partner GMP supply through KCT. Core capabilities: Adenoviral-Vector Vaccine Design, Nasal Delivery Formulation, Phase 1 Clinical Operations.
Editorial context
Related technical briefs
Briefs that name Kuopio as a covered market or city.